Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

First Posted Date
2012-02-02
Last Posted Date
2023-06-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
52
Registration Number
NCT01525394
Locations
🇺🇸

Charles River, Tacoma, Washington, United States

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase 1
Terminated
Conditions
Advanced Solid Tumors
Interventions
Drug: Golvatinib
Drug: Lenvatinib
First Posted Date
2011-09-14
Last Posted Date
2021-06-08
Lead Sponsor
Eisai Inc.
Target Recruit Count
30
Registration Number
NCT01433991
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

Phase 3
Completed
Conditions
Thyroid Cancer
Interventions
Drug: Placebo
Drug: Lenvatinib
First Posted Date
2011-03-23
Last Posted Date
2023-06-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
392
Registration Number
NCT01321554
Locations
🇬🇧

Facility 2, Manchester, United Kingdom

🇬🇧

Facility 3, London, United Kingdom

🇬🇧

Facility 1, Sutton, United Kingdom

and more 4 locations

A Study in Subjects With Recurrent Malignant Glioma

Phase 2
Completed
Conditions
Glioma
Interventions
Drug: Lenvatinib
Drug: Bevacizumab
First Posted Date
2010-06-04
Last Posted Date
2022-09-29
Lead Sponsor
Eisai Inc.
Target Recruit Count
151
Registration Number
NCT01137604

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2
Completed
Conditions
Unresectable Stage III
Stage IV Melanoma
Interventions
Drug: Lenvatinib
First Posted Date
2010-06-04
Last Posted Date
2019-11-13
Lead Sponsor
Eisai Inc.
Target Recruit Count
182
Registration Number
NCT01136967

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

First Posted Date
2010-06-03
Last Posted Date
2019-02-27
Lead Sponsor
Eisai Inc.
Target Recruit Count
173
Registration Number
NCT01136733

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

First Posted Date
2010-05-31
Last Posted Date
2023-06-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
7
Registration Number
NCT01133756
Locations
🇺🇸

Texas Oncology - Austin Central, Austin, Texas, United States

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1
Completed
Conditions
Stage IV Melanoma
Interventions
Drug: Lenvatinib
Drug: Dacarbazine
First Posted Date
2010-05-31
Last Posted Date
2016-10-10
Lead Sponsor
Eisai Inc.
Target Recruit Count
97
Registration Number
NCT01133977

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Phase 2
Completed
Conditions
Endometrial Cancer
Interventions
Drug: Lenvatinib
First Posted Date
2010-04-27
Last Posted Date
2023-06-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
133
Registration Number
NCT01111461

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Lenvatinib
First Posted Date
2009-07-24
Last Posted Date
2019-02-01
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
66
Registration Number
NCT00946153
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy